Terray Therapeutics announced a discovery milestone under its multi‑target collaboration with Bristol Myers Squibb, citing its EMMI platform and tArray hardware to find small molecules against a hard‑to‑drug target nominated by BMS. The company emphasized its high‑throughput binding dataset and AI‑driven workflows. Separately, the Baker lab released RFdiffusion3 as open source, demonstrating de novo design of DNA binders and advanced enzymes. RFdiffusion3’s all‑atom approach and faster runtime broaden AI protein design capabilities. Together these developments highlight rapid commercial and academic advances in AI‑driven molecular discovery, spanning proprietary hardware‑enabled datasets to open‑source generative protein models.